Holen Sie sich die Stockscreener-App
16.23
8.31%
-1.47
Handel nachbörslich:
16.31
0.08
+0.49%
Schlusskurs vom Vortag:
$17.70
Offen:
$17.77
24-Stunden-Volumen:
1.03M
Relative Volume:
1.06
Marktkapitalisierung:
$1.20B
Einnahmen:
$161.10M
Nettoeinkommen (Verlust:
$-308.60M
KGV:
-3.4754
EPS:
-4.67
Netto-Cashflow:
$-259.90M
1W Leistung:
-3.10%
1M Leistung:
-5.09%
6M Leistung:
-36.35%
1J Leistung:
-65.69%
1-Tages-Spanne:
$16.21
$18.00
1-Wochen-Bereich:
$16.21
$18.18
52-Wochen-Spanne:
$16.07
$49.76
Arvinas Inc Stock (ARVN) Company Profile
Firmenname
Arvinas Inc
Sektor
Branche
Telefon
203-535-1456
Adresse
395 WINCHESTER AVE, NEW HAVEN, CT
Vergleichen Sie ARVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
16.23 | 1.20B | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2024-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-01 | Eingeleitet | Goldman | Buy |
| 2023-12-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-11-20 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-10-23 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-01-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Eingeleitet | Barclays | Overweight |
| 2022-06-21 | Eingeleitet | Jefferies | Hold |
| 2022-05-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2022-01-19 | Eingeleitet | Goldman | Buy |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-09 | Eingeleitet | BofA Securities | Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-21 | Eingeleitet | Truist | Buy |
| 2021-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-12-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-12 | Eingeleitet | Oppenheimer | Perform |
| 2019-12-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-25 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-25 | Eingeleitet | Wedbush | Outperform |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-08-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-22 | Eingeleitet | Citigroup | Buy |
| 2018-10-22 | Eingeleitet | Goldman | Neutral |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Arvinas Inc Aktie (ARVN) Neueste Nachrichten
Wall Street Analysts Predict a 228.87% Upside in Arvinas (ARVN): Here's What You Should Know - Yahoo Finance
Arvinas, Inc. (NASDAQ:ARVN) Insider Sells $150,724.20 in Stock - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) CEO Sells $523,971.36 in Stock - MarketBeat
David K. Loomis Sells 1,214 Shares of Arvinas, Inc. (NASDAQ:ARVN) Stock - MarketBeat
Arvinas (NASDAQ:ARVN) Hits New 52-Week LowShould You Sell? - MarketBeat
Have Arvinas Insiders Been Selling Stock? - Simply Wall St
Arvinas’s SWOT analysis: biotech firm’s stock hinges on cancer drug trials - Investing.com
Arvinas chief scientific officer sells $70,238 in stock By Investing.com - Investing.com South Africa
Long Term Trading Analysis for (ARVN) - Stock Traders Daily
Arvinas president of R&D sells $150,752 in stock By Investing.com - Investing.com South Africa
Arvinas chief scientific officer sells $70,238 in stock - Investing.com
Arvinas Insider Sold Shares Worth $523,881, According to a Recent SEC Filing -February 25, 2025 at 06:49 am EST - Marketscreener.com
Arvinas president of R&D sells $150,752 in stock - Investing.com
Arvinas Executives Sell Shares to Cover Tax Obligations - TradingView
Arvinas (ARVN) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Arvinas stock hits 52-week low at $16.55 amid market challenges - Investing.com Australia
Arvinas stock hits 52-week low at $16.55 amid market challenges By Investing.com - Investing.com South Africa
Arvinas (NASDAQ:ARVN) Trading 7.4% HigherHere's What Happened - MarketBeat
Arvinas (NASDAQ:ARVN) shareholders have endured a 72% loss from investing in the stock three years ago - Yahoo Finance
Arvinas (ARVN) to Release Quarterly Earnings on Tuesday - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Sees Significant Growth in Short Interest - MarketBeat
All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy - MSN
Arvinas Operations describes new DGK-α inhibitors - BioWorld Online
What is HC Wainwright's Estimate for Arvinas Q3 Earnings? - MarketBeat
Wedbush Estimates Arvinas' Q1 Earnings (NASDAQ:ARVN) - MarketBeat
Earnings call transcript: Arvinas Q4 2024 surpasses EPS forecast, stock rises - Investing.com Nigeria
Q1 Earnings Forecast for Arvinas Issued By Leerink Partnrs - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Oppenheimer Forecasts Strong Price Appreciation for Arvinas (NASDAQ:ARVN) Stock - MarketBeat
Arvinas (NASDAQ:ARVN) Receives Buy Rating from Guggenheim - MarketBeat
Analysts Offer Predictions for Arvinas FY2029 Earnings - MarketBeat
Arvinas (NASDAQ:ARVN) Stock Price Up 5% Following Better-Than-Expected Earnings - MarketBeat
Arvinas (NASDAQ:ARVN) Given "Outperform" Rating at BMO Capital Markets - MarketBeat
Stifel Nicolaus Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock Price - MarketBeat
Wedbush Reiterates Outperform Rating for Arvinas (NASDAQ:ARVN) - MarketBeat
How the (ARVN) price action is used to our Advantage - Stock Traders Daily
Arvinas anticipates Phase 3 topline results for vepdegestrant in Q1 2025 with commercial preparations underway - MSN
Arvinas (NASDAQ:ARVN) Posts Quarterly Earnings Results, Beats Estimates By $0.44 EPS - MarketBeat
Finanzdaten der Arvinas Inc-Aktie (ARVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Arvinas Inc-Aktie (ARVN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cacace Angela M | Chief Scientific Officer |
Feb 24 '25 |
Sale |
16.70 |
4,207 |
70,238 |
97,231 |
| Taylor Ian | President, R&D |
Feb 24 '25 |
Sale |
16.71 |
9,020 |
150,752 |
159,121 |
| Houston John G | President and CEO |
Feb 24 '25 |
Sale |
16.72 |
31,338 |
523,881 |
1,157,480 |
6.45%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):